Evidence-Based Complementary and Alternative Medicine

Mistletoe: From Basic Research to Clinical Outcomes in Cancer and Other Indications


Publishing date
11 Apr 2014
Status
Published
Submission deadline
22 Nov 2013

1Department of Internal Medicine, Research Institute Havelhöhe (FIH), Havelhöhe Hospital; Institute of Social Medicine, Epidemiology and Health Economics, The Charité, Berlin, Germany

2School of Social and Community Medicine, University of Bristol, Bristol, UK

3Institute for Applied Epistemology and Medical Methodology at the University of Witten/Herdecke, Zechenweg 6, 79111 Freiburg, Germany

4Centre de Recherche des Cordeliers, Equipe 16-Immunopathology and Therapeutic Immunointervention, Université Pierre et Marie Curie-Paris 6, UMR S 872, 75006 Paris, France

5College of Medicine, Drexel University, Philadelphia, PA, USA


Mistletoe: From Basic Research to Clinical Outcomes in Cancer and Other Indications

Description

Mistletoe is a plant with a wide range of biologically active components, including lectins, viscotoxins, glycoproteins, and triterpenes. Over the past decade, in vitro research programmes have brought new insights, highlighting cytotoxic activity and specific immunological mechanisms including induction of apoptosis, necrosis, inhibition of angiogenesis, and an impact on both innate and adaptive immune compartments. This laboratory-based research is complemented by a range of clinical studies, from cohorts to randomized controlled trials and systematic reviews.

Mistletoe extracts are of particular interest in cancer treatment but are prescribed in traditional European naturopathic and anthroposophic medicine for a much wider range of indications, including: hypertension, coronary heart disease, and autoimmune conditions such as rheumatoid arthritis. Recent basic research has added antidiabetic effects of Viscum album to this list.

In central Europe, mistletoe therapy, even in an era of new chemotherapeutic and targeted therapies, is still the most commonly prescribed cancer treatment. Nevertheless, there is a gap between its wide spread use and the evidence of impact on long-term outcomes. Even in relation to quality of life and reduction of adverse effects of chemotherapy, there remains some uncertainty about the magnitude of benefit when administered alongside chemotherapy and radiotherapy. We invite authors to submit original research and systematic review papers. Potential topics include, but are not limited to:

  • New formulations
  • Biochemistry
  • Mistletoe lectins and viscotoxins
  • Triterpenes antiangiogenetic mechanisms
  • Immunology
  • Chronobiological application in daily clinical use
  • Cancer-related fatigue
  • Health-related quality of life
  • Clinical trials
  • Mistletoe as a component in whole system research
  • Outcome research
  • Meta-analysis
  • Indications other than cancer

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ecam/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/author/submit/journals/ecam/mistl/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2014
  • - Article ID 987527
  • - Editorial

Mistletoe: From Basic Research to Clinical Outcomes in Cancer and Other Indications

Matthias Kröz | Gunver Sophia Kienle | ... | Steven Rosenzweig
  • Special Issue
  • - Volume 2014
  • - Article ID 236310
  • - Research Article

Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study

Megan L. Steele | Jan Axtner | ... | Friedemann Schad
  • Special Issue
  • - Volume 2014
  • - Article ID 620974
  • - Research Article

Evaluation of Preclinical Assays to Investigate an Anthroposophic Pharmaceutical Process Applied to Mistletoe (Viscum album L.) Extracts

Stephan Baumgartner | Heidi Flückiger | ... | Konrad Urech
  • Special Issue
  • - Volume 2014
  • - Article ID 210198
  • - Research Article

A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients

Alessandra Longhi | Marcus Reif | ... | Stefano Ferrari
  • Special Issue
  • - Volume 2014
  • - Article ID 430518
  • - Research Article

Additional Therapy with a Mistletoe Product during Adjuvant Chemotherapy of Breast Cancer Patients Improves Quality of Life: An Open Randomized Clinical Pilot Trial

Wilfried Tröger | Zdravko Ždrale | ... | Miodrag Matijašević
  • Special Issue
  • - Volume 2014
  • - Article ID 606348
  • - Erratum

Erratum to “NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors”

Patrick J. Mansky | Dawn B. Wallerstedt | ... | Brian P. Monahan
  • Special Issue
  • - Volume 2014
  • - Article ID 724258
  • - Research Article

Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients

Megan L. Steele | Jan Axtner | ... | Friedemann Schad
  • Special Issue
  • - Volume 2013
  • - Article ID 718105
  • - Research Article

Effects of Lipophilic Extract of Viscum album L. and Oleanolic Acid on Migratory Activity of NIH/3T3 Fibroblasts and on HaCat Keratinocytes

R. Kuonen | U. Weissenstein | ... | S. Baumgartner
  • Special Issue
  • - Volume 2013
  • - Article ID 964592
  • - Research Article

NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors

Patrick J. Mansky | Dawn B. Wallerstedt | ... | Brian P. Monahan
Evidence-Based Complementary and Alternative Medicine
 Journal metrics
Acceptance rate27%
Submission to final decision68 days
Acceptance to publication33 days
CiteScore2.900
Impact Factor1.813
 Submit